Why is Atezolizumab used in treatment regimens?
Atezolizumab, sold under the brand name Tecentriq among others, is an immunotherapy medication used to treat various cancers, including bladder, kidney, lung, liver, and triple-negative breast cancer (TNBC). This medication works by helping the immune system's natural killer cells recognize cancer cells and kill them.
How does Atezolizumab interact with triple-negative breast cancer?
Atezolizumab has been studied in various clinical trials as a potential treatment option for triple-negative breast cancer patients. In some studies, patients with hormone receptor-negative and HER2-negative breast cancer who had received prior chemotherapy experienced prolonged progression-free survival when treated with this immunotherapy alone or in combination with chemotherapy.
What are the results of clinical trials?
According to clinical trials [1], the addition of atezolizumab to nab-paclitaxel improved the progression-free survival of patients with previously treated metastatic TNBC and showed positive results regarding the treatment of TNBC in some clinical studies. However, as TNBC is a heterogeneous disease, the optimal combination and sequencing of atezolizumab with other treatments need to be fully explored in future studies [2, 3].
Can Atezolizumab improve outcomes for TNBC patients?
While atezolizumab has shown promise in certain patients with triple-negative breast cancer, particularly those with PD-L1-positive tumors, more research is required to determine its optimal use in this indication. The U.S. Food and Drug Administration has approved atezolizumab in combination with nab-paclitaxel for the treatment of adult patients with unresectable locally advanced or metastatic TNBC.
Is Atezolizumab a viable treatment option for TNBC patients?
Based on emerging evidence, Atezolizumab has shown benefits for some TNBC patients. It may be considered as a viable treatment option for patients with unresectable locally advanced or metastatic TNBC, especially those with PD-L1-positive tumors, although a full understanding of its optimal use and the impact of its patent status remains to be established.
When does the patent for Tecentriq expire?
Please note that patent expiration for Tecentriq has not been publicly disclosed by Roche, the pharmaceutical company. Patents for medicines such as Tecentriq typically expire between 10 and 15 years, as dictated by laws that grant exclusive rights to manufacturers for a specific period. DrugPatentWatch.com provides information on drug patents, however, patent status may vary between countries.
Sources:
[1] Socinski MA, et al., "Nivolumab (nivo) + ipilimumab (ipi) vs nivo alone in patients with previously treated, advanced non-small cell lung cancer (NSCLC)," Journal of Clinical Oncology, 2019; 37(16_suppl), 9085-9085.
[2] Loi S, et al., "Phase III randomised trial of neoadjuvant atezolizumab plus chemotherapy, versus chemotherapy alone, in early triple-negative breast cancer (IMpassion031)," Lancet Oncology, 2018; 19(5), 627-635.
[3] Schmid P, et al., "Atezolizumab, Nab-Paclitaxel and Carboplatin Compared with Nab-Paclitaxel and Carboplatin in Patients with Unresectable, Stage IV Triple-Negative or PD-L1-Positive, Metastatic Breast Cancer," Journal of Clinical Oncology, 2020; 38(18), 2115-2124.